Ignite Creation Date:
2024-05-06 @ 12:31 AM
Last Modification Date:
2024-10-26 @ 10:51 AM
Study NCT ID:
NCT01595438
Status:
COMPLETED
Last Update Posted:
2017-09-06
First Post:
2012-04-27
Brief Title:
Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs Urinary Tract Infections
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime Avibactam CAZ-AVI Formerly CAZ104 Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized Adults
Status:
COMPLETED
Status Verified Date:
2017-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effects of Ceftazidime Avibactam compared to Doripenem for treating hospitalized patients with complicated urinary tract infections including acute pyelonephritis
Detailed Description:
A Phase III Randomized Multicenter Double-Blind Double Dummy Parallel Group Comparative Study to Determine the Efficacy Safety and Tolerability of Ceftazidime Avibactam CAZ-AVI formerly CAZ104 Versus Doripenem Followed by Appropriate Oral Therapy in the Treatment of Complicated Urinary Tract Infections Including Acute Pyelonephritis With a Gram Negative Pathogen in Hospitalized Adults
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-005721-43 | None | None | None |